MAPT and Alzheimer disease: Accumulating evidence suggests EC as one of the focal sites of disease progression in Alzheimer’s disease (AD), a neurodegenerative disease in which accumulation of amyloid-β (Aβ) and tau leads to synaptic, network and cognitive dysfunctions; In AD patients, the EC shows severe atrophy, with neuronal loss and dense Aβ accumulation (Hyman et al., 1984; Van Hoesen et al., 1991; Gomez-Isla et al., 1996).